|
Observation period, days, median [range]
|
740 [161–3278]
|
706 [153–2902]
|
0.708
|
|
Age, years, median [range]
|
74 [53–89]
|
66 [34–86]
|
0.001
|
|
Sex (men/women), n
|
14/17
|
56/15
|
0.001
|
|
BMI in men, kg/m2, median [range]
|
21.0 [16.2–25.8]
|
24.4 [19.7–33.8]
|
< 0.001
|
|
BMI in women, kg/m2, median [range]
|
22.0 [16.0–37.5]
|
23.9 [20.7–34.7]
|
0.009
|
|
Baseline L3 SMI in men, cm2/m2, median [range]
|
36.8 [31.5–40.7]
|
48.2 [42.2–64.4]
|
< 0.001
|
|
Baseline L3 SMI in women, cm2/m2, median [range]
|
34.4 [25.6–36.5]
|
41.7 [38.1–55.6]
|
< 0.001
|
|
Etiology (HBV/HCV/NBNC), n
|
1/23/7
|
10/27/34
|
0.003
|
|
ALT, U/L, median [range]
|
38 [13–123]
|
37 [9–243]
|
0.945
|
|
Total bilirubin, mg/dL, median [range]
|
0.8 [0.5–2.7]
|
1.0 [0.4–3.5]
|
0.107
|
|
Albumin, g/dL, median [range]
|
3.6 [2.1–4.7]
|
3.7 [2.0–4.9]
|
0.249
|
|
Platelet count, × 104/μL, median [range]
|
11.6 [3.2–61.5]
|
12.1 [2.2–80.9]
|
0.636
|
|
Child-Pugh classification (A/B), n
|
20/11
|
48/23
|
0.821
|
|
AFP, ng/mL, median [range]
|
19.5 [2.1–633,900]
|
24.7 [1.0–285,973]
|
0.881
|
|
TNM stage (I + II/III + IV), n
|
9/22
|
24/47
|
0.818
|
|
Maximum tumor diameter, mm, median [range]
|
26 [13–150]
|
36 [9–198]
|
0.662
|
|
Number of tumors (solitary/multiple), n
|
9/22
|
20/51
|
1.000
|
|
Treatment sessions between CT exams (1/≥2, sessions), n
|
17/14
|
42/29
|
0.828
|
|
mRECIST assessment (non-PD/PD), n
|
16/15
|
37/34
|
1.000
|
|
BCAA supplementation (presence/absence), n
|
22/9
|
50/21
|
1.000
|
